Great Bear Resources Ltd. (GTBAF)(GBR:CA) – High-Grade Zones Coming Into Clearer View

Thursday, May 20, 2021

Great Bear Resources Ltd. (GTBAF)(GBR:CA)
High-Grade Zones Coming Into Clearer View

Noble Capital Markets research on Great Bear Resources is published under ticker symbols GTBAF and GBR:CA. The price target is in USD and based on ticker symbol GTBAF. Great Bear Resources Ltd is a gold exploration company. It explores for mineral properties in the Red Lake District in Ontario, Canada. Its property portfolio includes Great Bear’s Red Lake Properties with the flagship Dixie project, Pakwash property, and Sobel property.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Getting more granular. Great Bear released additional drill results which featured high-grade gold intercepts with significant drill indicated core lengths, and reinforced the continuity of high-grade and bulk-tonnage gold mineralization within the LP Fault. Including results for the most recent 17 drill holes, Great Bear has released 300 LP Fault drill holes to date and expects to complete 400 by year-end. The company is modeling 17 distinct high-grade gold domains within the broader LP Fault gold mineralized system. Together, they encompass a strike length of 4.2 kilometers and occur within eight larger lower grade domains. Importantly, Great Bear provided a detailed long section of the upper portion of one of the high-grade domains, a summary of all drill results within the long section, and detailed maps of the high-grade domains within the broader LP Fault gold system.

    Positive implications.  The release of more detailed information about the distinct high-grade gold domains should make it easier for investors to gauge the project’s mineral resource potential. Additionally, it has implications for mine planning as we think the company may have the ability to size a smaller mill and focus on higher grade material initially which could result in robust project …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

The Sustainability of Growing Margin Debt


image credit: Mikhail Nilov (Pexels)


Margin Debt Increases are Eye-Popping

 

Stock market margin debt jumped by $25 billion in April and $48.5 billion since the beginning of the year based on FINRA statistics. The level reached a historic high of $847 billion from $552.5 billion a year ago. This 53% increase in a year is growth well above average. The unsustainability of this pace, and the idea that margin rates charged by brokers will rise as interest rates do, add an overlooked element of risk in today’s stock market.

The seeming precariousness of the level of leverage measures only two types of accounts, this includes brokerage accounts and advisory customers that are overseen by FINRA. It excludes unreported borrowing by professionals and others that have used debt for investments in the financial markets.

 

 

The below graph shows weekly data on the growth of margin debt reported by FINRA. The current pace is faster than at any point found on the FINRA website. The market, as measured by the S&P 500, is following the same path of growth (see second chart). Although correlation is not proof of cause; experience has shown that as the market rises, people will borrow to compound their returns. Further, as the value of the accounts that serve as collateral then rise, they are capable of leveraging up even more.

 

 

The snowball effect of the increases in both the S&P performance and the borrowing that is in part fueling the market increases could continue until something disrupts the chain reaction.

 

Possible Disruptors to Margin and Market Growth

This disruption could come in the form of an increase in interest rates. This would cause brokers to raise their broker’s call rate.  Investors would then have to weigh their expected return versus the cost of the borrowing. The cost of borrowed funds to the expected return equation would not be as favorable even if their market view has not changed. This could cause some investors to retreat from their aggressive position. It wouldn’t take much at these levels to create a chain reaction of selling to reduce borrowed capital.

Another potential disruptor could be a few bad days in a row for the market. Again this impacts expected return versus the cost of (borrowed) money. The chart above suggests just how large the profits are that many investors are sitting on. A few days of market decline can signal ti investors that it’s time to book some of those profits. This further weakness could trigger enough margin calls where investors either sell positions and pay off the interest, or cough up additional cash. The margin calls could create a march downward as the same forces that brought it up, act in reverse to tear it down.

 

 

Other Borrowing

In a previous article, Channelchek reported that 2.5 million homes or 4.9% of homeowners’ mortgages are in forbearance. The hurdle to pause payment on a federal agency-backed mortgage is quite low. It’s suspected that some of this money that will be owed later has been finding its way into the market. In reality, this is borrowed money, and the payments are (under current stipulations) required to resume by mid-year 2021. This could curtail the flow of these borrowed funds, not accounted for by FINRA, from entering the market. The reduced inflows and possible outflows would reduce investment growth and the upward pressure on prices.

In another Channelchek article, we described how family offices are not overseen by regulatory authorities like FINRA, any borrowing from money managers is not accounted for in much the same way hedge fund borrowing is not regulated or overseen. The leverage from these investment groups is not known. Earlier this year, there was an instance when the firm Archegos Capital Management suffered losses large enough to impact markets and earnings of some of their large banking relationships. The amount of risk and, therefore, the potential impact on the market to trade-off from this category is not known.

 

Take-Away

The strength of the market comes from many places. The amount of cash in the system undoubtedly has driven prices up. The low return on interest rate investment alternatives is another which pushed money into higher-risk investments, and then there is the availability of borrowed money. The use of borrowed money is at historic highs.

Borrowed money has a cost. That cost is measured against the expected return. If the expectations change or the cost of money increases, the market could sink to find a new balance from which to try to build again. Just as sure as markets go up and down, this will occur to some degree. Why a selloff may be triggered is debt-funded investing. When a larger selloff may be triggered, is unknown.

 

Suggested Reading:

Is Inflation Going to Hurt Stocks?

The Limits of Government Economic Tinkering (June 2020)



A Look at Real Estate Risks to the Stock Market

Understanding Family Offices

 

Sources:

https://www.finra.org/investors/learn-to-invest/advanced-investing/margin-statistics

https://www.federalreserve.gov/publications/files/financial-stability-report-20210506.pdf

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – EuroDry Ltd. Reports Results for the Quarter Ended March 31 2021


EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2021 and Announces Agreement to Acquire M/V Blessed Luck, a 2004-Japanese Built Panamax Bulker

 

ATHENS, Greece, May 20, 2021 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three-month period ended March 31, 2021 and an agreement to acquire M/V Blessed Luck, a 76,704 dwt drybulk vessel built in Japan.

First Quarter 2021 Highlights:

  • Total net revenues of $8.6 million; net income of $0.9 million; net income attributable to common shareholders (after a $0.3 million dividend on Series B Preferred Shares and a $0.1 million preferred deemed dividend arising out of the net redemption of approximately $3 million of Series B Preferred Shares in the first quarter of 2021) of $0.4 million or $0.19 earnings per share basic and diluted. Adjusted net income attributable to common shareholders1 for the period was $1.3 million or $0.55 earnings per share basic and diluted.
  • Adjusted EBITDA1 was $4.0 million.
  • An average of 7.0 vessels were owned and operated during the first quarter of 2021 earning an average time charter equivalent rate of $14,924 per day.
  • The Company declared a dividend of $0.3 million on its Series B Preferred Shares. The dividend will be paid in cash.

1Adjusted EBITDA, Adjusted net income/(loss) and Adjusted earnings/(loss) per share are not recognized measurements under US GAAP (GAAP) and should not be used in isolation or as a substitute for EuroDry’s financial results presented in accordance with GAAP. Refer to a subsequent section of the Press Release for the definitions and reconciliation of these measurements to the most directly comparable financial measures calculated and presented in accordance with GAAP.

M/V Blessed Luck Acquisition

The Company also announced that it has agreed to acquire M/V Blessed Luck, a 76,704 dwt drybulk vessel built in 2004 in Japan, for $12.12 million. The vessel is majority owned by a third party and has been managed by Eurobulk Ltd., also the manager of three of the Company’s vessels. The vessel is expected to be delivered to the Company within May 2021. The acquisition will be financed partly by a short term sellers’ credit of $5 million and an one year bridge loan of $6 million provided by an entity affiliated with the Company’s Chief Executive Officer with the remaining funds coming from the Company; both the sellers’ credit and short term loan carry an annual interest of 8%. In parallel, the Company is in the process of arranging a bank loan with the acquired vessel as collateral, expected to be finalized within approximately three months, which will provide sufficient funds to repay the sellers’ credit and, possibly, part of the bridge loan. At the same time, the Company entered into a charter agreement for the vessel for a period between a minimum of 11 months and a maximum of 13 months at a rate of $19,500/day which will commence upon delivery of the vessel and contribute about $4 million of EBITDA during the minimum period of the charter.

Aristides Pittas, Chairman and CEO of EuroDry commented:
“In stark contrast to a year ago, it has been a very positive 2021 so far with drybulk rates rebounding significantly as a result of solid trade growth and limited supply growth. The latter, especially, is constrained by short and medium term factors: in the short term, by inefficiencies in the vessel-port transportation system that resulted from COVID-19 effects and required protocols and, in the medium term, by the lowest orderbook in the last 20+ years. We believe that the market is likely to remain strong for the next couple of years provided that demand for transportation of drybulk cargoes – which is generally linked to economic activity – will maintain at least a historically average growth rate; it is noteworthy that the IMF, amongst others, predicts that economic activity will rebound above historical average levels as the world recovers from the COVID-19 pandemic.

In such a positive environment, our main strategy is to try to expand our fleet in a risk efficient way despite our limited funds available for investment. Thus, we acquired M/V Blessed Luck, a 2004-built vessel, with a combination of seller and affiliate bridge loans to complement our cluster of medium age Japanese-built Panamax-size vessels alongside our cluster of own-built newbuildings. The acquisition of M/V Blessed Luck will increase our fleet to eight units and is expected to contribute to a proportional increase in our EBITDA. At the present market rate levels, we are to accumulate funds that will provide us with several investment or expansion options or shareholder reward models. We, further, believe that the strong drybulk markets enhance the value of our public listing as a consolidation platform and we continuously investigate opportunities to take advantage of it.”

Tasos Aslidis, Chief Financial Officer of EuroDry commented:
“Our net revenues for the first quarter of 2021 were higher by 69.3% as compared to the first quarter of 2020. This was the result of higher average charter rates by 89.3% earned during the quarter as compared to the first quarter of 2020 and 38.7% higher when compared to the fourth quarter of 2020.

Total daily vessel operating expenses, including management fees, general and administrative expenses, but excluding drydocking costs, increased by approximately 8.5% during the first quarter of 2021 compared to the same quarter of last year. This increase is mainly due to increased crewing costs in 2021 compared to 2020, resulting from difficulties in crew rotation due to COVID-19 related restrictions.

Adjusted EBITDA during the first quarter of 2021 was $4.0 million compared to $0.6 million achieved for the first quarter of last year. As of March 31, 2021, our outstanding debt (excluding the unamortized loan fees) was $56.0 million versus restricted and unrestricted cash of approximately $6.2 million.”

First Quarter 2021 Results:
For the first quarter of 2021, the Company reported total net revenues of $8.6 million representing a 69.3% increase over total net revenues of $5.1 million during the first quarter of 2020, which was the result of the higher time charter rates our vessels earned during the first quarter of 2021. The Company reported net income for the period of $0.9 million and net income attributable to common shareholders of $0.4 million, as compared to a net loss and a net loss attributable to common shareholders of $2.3 million and $2.6 million, respectively, for the same period of 2020. For the first quarter of 2021, a gain on bunkers resulted in positive voyage expenses of $0.3 million for the period as compared to voyage expenses of $0.4 million in the same period of 2020. Depreciation expenses for the first quarter of 2021 were $1.7 million compared to $1.6 million for the same period of 2020. Vessel operating expenses were $3.1 million for the first quarter of 2021 compared to $2.8 million in the same period of 2020, mainly due to increased crewing costs in the first quarter of 2021 compared to the corresponding period in 2020, resulting from difficulties in crew rotation due to COVID-19 related restrictions. Management fees and general and administrative expenses remained unchanged at $0.5 million and $0.6 million, respectively, for the first quarter of 2021 as compared to the same period of last year.

Interest and other financing costs for the first quarter of 2021 amounted to $0.6 million, slightly decreased as compared to $0.7 million for the same period of 2020. Interest during the first quarter of 2021 was lower due to lower average debt during the period and the decreased Libor rates of our loans during the period as compared to the same period of last year. For the three months ended March 31, 2021, the Company recognized a $1.6 million loss on derivatives, comprised of $0.7 million realized loss and $1.1 million unrealized loss of forward freight agreements and $0.2 million gain on three interest rate swaps as compared to a loss on interest rate swaps of $0.3 million for the same period of 2020.

On average, 7.0 vessels were owned and operated during the first quarter of 2021 earning an average time charter equivalent rate of $14,924 per day compared to 7.0 vessels in the same period of 2020 earning on average $7,885 per day.

Adjusted EBITDA for the first quarter of 2021 was $4.0 million compared to $0.6 million achieved during the first quarter of 2020.

Basic and diluted earnings per share attributable to common shareholders for the first quarter of 2021 was $0.19 calculated on 2,291,471 basic and 2,320,577 diluted weighted average number of shares outstanding, compared to basic and diluted loss per share of $1.17 for the first quarter of 2020, calculated on 2,267,375 basic and diluted weighted average number of shares outstanding.

Excluding the effect on the earnings attributable to common shareholders for the quarter of the unrealized loss on derivatives, the adjusted earnings attributable to common shareholders for the quarter ended March 31, 2021 would have been $0.55 per share basic and diluted, compared to an adjusted loss of $0.91 per share basic and diluted for the quarter ended March 31, 2020, after excluding the effect of the unrealized loss on derivatives and the loss on write-down of inventory. Usually, security analysts do not include the above items in their published estimates of earnings per share.

Fleet Profile:

The EuroDry Ltd. fleet profile is as follows:

Name Type Dwt Year
Built
Employment(*) TCE Rate ($/day)
Dry Bulk Vessels          
EKATERINI Kamsarmax 82,000 2018 TC until Mar-22 Hire 106% of the
Average Baltic
Kamsarmax P5TC(***)
index
XENIA Kamsarmax 82,000 2016 TC until Aug-22 Hire 105% of the
Average Baltic
P5TC(***) index
ALEXANDROS P. Ultramax 63,500 2017 Guardian
Navigation GMax
LLC Pool
Pool revenue from
August 2018
EIRINI P Panamax 76,466 2004 TC until Jun-21 Hire 99%
of Average
BPI(**) 4TC
STARLIGHT Panamax 75,845 2004 TC until Aug-21 Hire 98.5%
of Average
BPI(**) 4TC
TASOS Panamax 75,100 2000 TC until Jun-21 $19,750
PANTELIS Panamax 74,020 2000 TC until May-21 $10,450
Total Dry Bulk Vessels 7
528,931      
Vessel agreed to be acquired          
BLESSED LUCK
Panamax 76,704 2004 TC until April-22 $19,500
Total on a fully delivered basis 8 605,635      

Note:
(*)        Represents the earliest redelivery date.
(**)      BPI stands for the Baltic Panamax Index; the average BPI 4TC is an index based on four time charter routes.
(***)    The average Kamsarmax Baltic P5TC Index is an index based on five Panamax time charter routes.



Summary Fleet Data:

  Three months,
ended

March 31, 2020
Three months,
ended

March 31, 2021
FLEET DATA    
Average number of vessels (1) 7.0   7.0  
Calendar days for fleet (2) 637.0   630.0  
Scheduled off-hire days incl. laid-up (3) 9.9   0.0  
Available days for fleet (4) = (2) – (3) 627.1   630.0  
Commercial off-hire days (5) 0.0   0.0  
Operational off-hire days (6) 0.0   0.0  
Voyage days for fleet (7) = (4) – (5) – (6) 627.1   630.0  
Fleet utilization (8) = (7) / (4) 100.0 % 100.0 %
Fleet utilization, commercial (9) = ((4) – (5)) / (4) 100.0 % 100.0 %
Fleet utilization, operational (10) = ((4) – (6)) / (4) 100.0 % 100.0 %
     
AVERAGE DAILY RESULTS    
Time charter equivalent rate (11) 7,885   14,924  
Vessel operating expenses excl. drydocking expenses (12) 5,130   5,694  
General and administrative expenses (13) 925   877  
Total vessel operating expenses (14) 6,055   6,571  
Drydocking expenses (15) 342   13  

(1) Average number of vessels is the number of vessels that constituted the Company’s fleet for the relevant period, as measured by the sum of the number of calendar days each vessel was a part of the Company’s fleet during the period divided by the number of calendar days in that period.

(2) Calendar days. We define calendar days as the total number of days in a period during which each vessel in our fleet was owned by us including off-hire days associated with major repairs, drydockings or special or intermediate surveys or days of vessels in lay-up. Calendar days are an indicator of the size of our fleet over a period and affect both the amount of revenues and the amount of expenses that we record during that period.

(3) The scheduled off-hire days including vessels laid-up are days associated with scheduled repairs, drydockings or special or intermediate surveys or days of vessels in lay-up.

(4) Available days. We define available days as the total number of Calendar days in a period net of scheduled off-hire days incl. laid up. We use available days to measure the number of days in a period during which vessels were available to generate revenues.

(5) Commercial off-hire days. We define commercial off-hire days as days a vessel is idle without employment.

(6) Operational off-hire days. We define operational off-hire days as days associated with unscheduled repairs or other off-hire time related to the operation of the vessels.

(7) Voyage days. We define voyage days as the total number of days in a period during which each vessel in our fleet was in our possession net of commercial and operational off-hire days. We use voyage days to measure the number of days in a period during which vessels actually generate revenues or are sailing for repositioning purposes.

(8) Fleet utilization. We calculate fleet utilization by dividing the number of our voyage days during a period by the number of our available days during that period. We use fleet utilization to measure a company’s efficiency in finding suitable employment for its vessels and minimizing the amount of days that its vessels are off-hire for reasons such as unscheduled repairs or days waiting to find employment.

(9) Fleet utilization, commercial. We calculate commercial fleet utilization by dividing our available days net of commercial off-hire days during a period by our available days during that period.

(10) Fleet utilization, operational. We calculate operational fleet utilization by dividing our available days net of operational off-hire days during a period by our available days during that period.

(11) Time charter equivalent rate, or TCE, is a measure of the average daily net revenue performance of our vessels. Our method of calculating TCE is determined by dividing time charter revenue and voyage charter revenue net of voyage expenses by voyage days for the relevant time period. Voyage expenses primarily consist of port, canal and fuel costs that are unique to a particular voyage, which would otherwise be paid by the charterer under a time charter contract or are related to repositioning the vessel for the next charter. TCE is a standard shipping industry performance measure used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., spot voyage charters, time charters, pool agreements and bareboat charters) under which the vessels may be employed between the periods. Our definition of TCE may not be comparable to that used by other companies in the shipping industry.

(12) Daily vessel operating expenses, which include crew costs, provisions, deck and engine stores, lubricating oil, insurance, maintenance and repairs and management fees are calculated by dividing vessel operating expenses and management fees by fleet calendar days for the relevant time period. Drydocking expenses are reported separately.

(13) Daily general and administrative expense is calculated by dividing general and administrative expenses by fleet calendar days for the relevant time period.

(14) Total vessel operating expenses, or TVOE, is a measure of our total expenses associated with operating our vessels. TVOE is the sum of vessel operating expenses, management fees and general and administrative expenses; drydocking expenses are not included. Daily TVOE is calculated by dividing TVOE by fleet calendar days for the relevant time period.

(15) Drydocking expenses include expenses during drydockings that would have been capitalized and amortized under the deferral method divided by the fleet calendar days for the relevant period. Drydocking expenses could vary substantially from period to period depending on how many vessels underwent drydocking during the period. The Company expenses drydocking expenses as incurred.

Conference Call and Webcast:
Today, May 20, 2021 at 09:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results. 

Conference Call details:
Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553-9962 (US Toll Free Dial In), 0(808) 238- 0669 (UK Toll Free Dial In) or +44 (0) 2071 928592 (Standard International Dial In). Please quote “EuroDry” to the operator. 

A replay of the conference call will be available until Thursday, May 27, 2021. The United States replay number is 1(866) 331-1332; from the UK 0(808) 238-0667; the standard international replay number is (+44) (0) 3333 00 9785 and the access code required for the replay is: 2489743#.  

Audio webcast – Slides Presentation:
There will be a live and then archived audio webcast of the conference call, via the internet through the EuroDry website (www.eurodry.gr). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. A slide presentation on the First Quarter 2021 results in PDF format will also be available 10 minutes prior to the conference call and webcast accessible on the company’s website (www.eurodry.gr) on the webcast page. Participants to the webcast can download the PDF presentation. 


EuroDry Ltd.
Unaudited Consolidated Condensed Statements of Operations
(All amounts expressed in U.S. Dollars – except number of shares)

  Three Months
Ended

March 31,
Three Months
Ended

March 31,
  2020
2021
   
Revenues    
Time charter revenue 5,345,554   9,096,187  
Commissions (280,046 ) (522,486 )


Net revenues
5,065,508   8,573,701  
     
Operating expenses    
Voyage expenses, net 400,637   (305,902 )
Vessel operating expenses 2,778,543   3,061,055  
Drydocking expenses 217,675   7,921  
Vessel depreciation 1,626,258   1,651,870  
Related party management fees 489,566   526,400  
General and administrative expenses 589,534   552,523  
Loss on write-down of inventory 255,200    
Total Operating expenses (6,357,413 ) (5,493,867 )
     
Operating (loss) / income (1,291,905 ) 3,079,834  
     
Other income / (expenses)    
Interest and other financing costs (664,427 ) (595,817 )
Loss on derivatives, net (340,976 ) (1,620,344 )
Foreign exchange gain / (loss) 669   (2,472 )
Interest income 3,544   3,325  
Other expenses, net (1,001,190 ) (2,215,308 )
Net (loss) / income (2,293,095 ) 864,526  
Dividend Series B Preferred shares (354,826 ) (299,570 )
Preferred deemed dividend   (120,000 )
Net (loss) / income attributable to common shareholders (2,647,921 ) 444,956  
(Loss) / earnings per share, basic & diluted (1.17 ) 0.19  
Weighted average number of shares, basic 2,267,375   2,291,471  
Weighted average number of shares, diluted 2,267,375   2,320,577  


EuroDry Ltd.
Unaudited Consolidated Condensed Balance Sheets
(All amounts expressed in U.S. Dollars – except number of shares)

  December 31,
2020
March 31,
2021
     
ASSETS  
Current Assets:    
Cash and cash equivalents 938,282   2,085,456  
Trade accounts receivable, net 1,528,055   2,663,752  
Other receivables 460,209   537,313  
Inventories 1,385,280   487,280  
Restricted cash 1,518,036   2,198,274  
Prepaid expenses 226,033   173,037  
Due from related companies   387,393  
Total current assets 6,055,895   8,532,505  
     
Fixed assets:    
Vessels, net 99,305,990   97,678,758  
Long-term assets:    
Restricted cash 2,150,000   1,900,000  
Total assets 107,511,885   108,111,263  
     
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY    
Current liabilities:    
Long term bank loans, current portion 13,793,754   14,100,581  
Trade accounts payable 1,074,518   907,155  
Accrued expenses 704,508   719,363  
Accrued preferred dividends   299,570  
Derivatives 456,133   1,543,641  
Deferred revenue 246,125   665,504  
Due to related companies 2,984,759    
Total current liabilities 19,259,797   18,235,814  
     
Long-term liabilities:    
Long term bank loans, net of current portion 37,318,084   41,588,509  
Derivatives 393,899   128,191  
Total long-term liabilities 37,711,983   41,716,700  
Total liabilities 56,971,780   59,952,514  
     
Mezzanine equity:        
Series B Preferred shares (par value $0.01, 20,000,000 preferred shares authorized, 16,606 and 13,606 shares issued and outstanding, respectively) 15,940,713   13,060,713  
     
Shareholders’ equity:    
Common stock (par value $0.01, 200,000,000 shares authorized, 2,348,216 issued and outstanding, respectively) 23,482   23,482  
Additional paid-in capital 53,048,060   53,101,748  
Accumulated deficit (18,472,150 ) (18,027,194 )
Total shareholders’ equity 34,599,392   35,098,036  
Total liabilities, mezzanine equity and shareholders’ equity 107,511,885   108,111,263  
     


EuroDry Ltd.
Unaudited Consolidated Condensed Statements of Cash Flows
(All amounts expressed in U.S. Dollars)

  Three Months
Ended March
31,
  Three Months
Ended March
31,
 
2020   2021  
     
Cash flows from operating activities:  
Net (loss) / income (2,293,095 ) 864,526  
Adjustments to reconcile net (loss) / income to net cash provided by / (used in) operating activities:    
Vessel depreciation 1,626,258   1,651,870  
Amortization and write off of deferred charges 35,176   169,251  
Share-based compensation 62,106   53,688  
Loss on write-down of inventory 255,200    
Unrealized loss on derivatives 329,047   821,801  
Changes in operating assets and liabilities (206,623 ) (3,360,484 )
Net cash (used in) / provided by operating activities (191,931 ) 200,562  
     
Cash flows from investing activities:    
Cash paid for vessels capitalized expenses (189,950 ) (31,240 )
Net cash used in investing activities (189,950 ) (31,240 )
     
Cash flows from financing activities:    
Redemption of preferred shares   (3,000,000 )
Preferred dividends paid (358,726 )  
Loan arrangement fees paid   (250,000 )
Proceeds from long-term debt   31,700,000  
Repayment of long-term debt (2,002,000 ) (27,042,000 )
Net cash (used in) / provided by financing activities (2,360,726 ) 1,408,000  
     
Net increase / (decrease) in cash, cash equivalents and restricted cash (2,742,607 ) 1,577,412  
Cash, cash equivalents and restricted cash at beginning of period
9,129,442   4,606,318  
Cash, cash equivalents and restricted cash at end of period 6,386,835   6,183,730  
     

Cash breakdown

Cash and cash equivalents 3,284,024   2,085,456  
Restricted cash, current 402,811   2,198,274  
Restricted cash, long term 2,700,000   1,900,000  
Total cash, cash equivalents and restricted cash shown in the statement of cash flows 6,386,835   6,183,730  


EuroDry Ltd.
Reconciliation of Adjusted EBITDA to Net (loss) / income
(All amounts expressed in U.S. Dollars)

  Three Months
Ended

March 31, 2020
Three Months
Ended

March 31, 2021
Net (loss) / income (2,293,095 ) 864,526  
Interest and other financing costs, net (incl. interest income) 660,883   592,492  
Vessel depreciation 1,626,258   1,651,870  
Unrealized loss on Forward Freight Agreement derivatives   1,069,980  
Loss / (gain) on interest rate swap derivatives 340,976   (174,513 )
Loss on write-down of inventory 255,200    

Adjusted EBITDA
590,222   4,004,354  

Adjusted EBITDA Reconciliation:
EuroDry Ltd. considers Adjusted EBITDA to represent net income / (loss) before interest, income taxes, depreciation, unrealized (gain) / loss on Forward Freight Agreements (FFAs), (gain) / loss on interest rate swaps and loss on write-down of inventory. Adjusted EBITDA does not represent and should not be considered as an alternative to net income / (loss), as determined by United States generally accepted accounting principles, or GAAP. Adjusted EBITDA is included herein because it is a basis upon which the Company assesses its financial performance because the Company believes that this non-GAAP financial measure assists our management and investors by increasing the comparability of our performance from period to period by excluding the potentially disparate effects between periods of, financial costs, unrealized (gain) / loss on FFAs, (gain) / loss on interest rate swaps, loss on write-down of inventory, and depreciation. The Company’s definition of Adjusted EBITDA may not be the same as that used by other companies in the shipping or other industries. 

EuroDry Ltd.
Reconciliation of Net (loss) / income to Adjusted net (loss) / income
(All amounts expressed in U.S. Dollars – except share data and number of shares)

  Three Months
Ended
March 31, 2020
Three Months
Ended
March 31, 2021
 
Net (loss) / income (2,293,095 ) 864,526  
Unrealized loss on derivatives 329,047   821,801  
Loss on write-down of inventory 255,200    
Adjusted net (loss) / income (1,708,848 ) 1,686,327  
Preferred dividends (354,826 ) (299,570 )
Preferred deemed dividend   (120,000)  

Adjusted net (loss) / income attributable to common shareholders
(2,063,674 ) 1,266,757  
Adjusted (loss) / earnings per share, basic & diluted (0.91 ) 0.55  
Weighted average number of shares, basic 2,267,375   2,291,471  
Weighted average number of shares, diluted 2,267,375   2,320,577  

Adjusted net income / (loss) and Adjusted income / (loss) per share Reconciliation:

EuroDry Ltd. considers Adjusted net income / (loss) to represent net income / (loss) before unrealized (gain) / loss on derivatives and loss on write-down of inventory. Adjusted net income / (loss) and Adjusted earnings / (loss) per share is included herein because we believe it assists our management and investors by increasing the comparability of the Company’s fundamental performance from period to period by excluding the potentially disparate effects between periods of unrealized (gain) / loss on derivatives and loss on write-down of inventory, which may significantly affect results of operations between periods. Adjusted net income / (loss) and Adjusted earnings / (loss) per share do not represent and should not be considered as an alternative to net income / (loss) or earnings / (loss) per share, as determined by GAAP. The Company’s definition of Adjusted net income / (loss) and Adjusted earnings / (loss) per share may not be the same as that used by other companies in the shipping or other industries.

About EuroDry Ltd.
EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd into a separate listed public company. EuroDry was spun-off from Euroseas Ltd on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. 

EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day-to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

After the delivery of M/V Blessed Luck, the Company will have a fleet of 8 vessels, including 5 Panamax drybulk carriers, 1 Ultramax drybulk carrier and 2 Kamsarmax drybulk carriers. EuroDry’s 8 drybulk carriers have a total cargo capacity of 605,635 dwt.

Forward Looking Statement
This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for dry bulk vessels, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

Visit our website www.eurodry.gr

Company Contact Investor Relations / Financial Media
Tasos Aslidis
Chief Financial Officer
EuroDry Ltd.
11 Canterbury Lane,
Watchung, NJ07069
Tel. (908) 301-9091
E-mail: [email protected]
Nicolas Bornozis
President
Capital Link, Inc.
230 Park Avenue, Suite 1536
New York, NY10169
Tel. (212) 661-7566
E-mail: [email protected]

QuickChek – May 20, 2021



EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2021 and Announces Agreement to Acquire M/V Blessed Luck, a 2004-Japanese Built Panamax Bulker

EuroDry Ltd announced its results for the three-month period ended March 31, 2021

Research, News & Market Data on EuroDry

Watch recent presentation from NobleCon17



PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

PDS Biotechnology announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO)

Research, News & Market Data on PDS Biotech

Watch recent presentation from PDS Biotech



Esports Entertainment Group, Inc. Reports Fiscal 2021 Third Quarter Financial Results

Esports Entertainment Group announced financial results for its fiscal 2021 third quarter ended March 31, 2021

Olympic Esports Involvement Can Serve Investors Well

Research, News & Market Data on Esports Entertainment Group

Watch recent presentation from EEG



Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares

Onconova Therapeutics announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021

Onconova reports Q1 2021 Financial Results

Research, News & Market Data on Onconova

Watch recent presentation from NobleCon17



Orion Group Holdings, Inc. Announces Contract Awards of Approximately $17 Million

Orion Group Holdings announced three contract awards for its Concrete segment in each of its key markets, totaling approximately $17 million

See today’s research report on Orion Group Holdings from Poe Fratt, Senior Research Analyst at Noble Capital Markets

Research, News & Market Data on Orion Group Holdings

Watch recent presentation from NobleCon17



Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights

Ceapro Inc. announced financial results and operational highlights for the first quarter ended March 31, 2021

Research, News & Market Data on Ceapro

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

 


PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

 

Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy

FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8. The presentation, scheduled for June 7, is expected to include results from a larger sample than the 14 patients included in the abstract.

Additional data highlights from abstract #2501 include:

  • An overall objective response rate of 71% (10/14) in patients with refractory HPV16-associated cancers
    • 1 complete response (anal cancer)
    • 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal cancer, 2 oropharyngeal cancer)
  • 90% of these of these responses are ongoing after a median 5 months of follow up (9/10)

The NCI Center for Cancer Research’s Laboratory of Tumor Immunology and Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading this Phase 2 trial (NCT04287868), which studies PDS0101 in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824), a bifunctional “trap” fusion protein targeting TGF-? and PD-L1, and NHS-IL12 (M9241), a tumor-targeting immunocytokine. Bintrafusp alfa is being jointly developed by Merck KGaA, Darmstadt, Germany, and GlaxoSmithKline; NHS-IL12 is being developed by Merck KGaA, Darmstadt, Germany.

The trial is evaluating the treatment combination in both checkpoint inhibitor naïve and refractory patients with advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment. Objective response is measured by radiographic tumor responses according to RECIST 1.1. These reported data validate the preclinical studies published by the NCI demonstrating that the complementary mechanisms of action of the three immunotherapies which involve potent in-vivo HPV16-specific killer and helper T-cell induction with effective T-cell tumor infiltration, blocking of immune checkpoints as well as targeting of TGF-? resulted in superior tumor regression.

“The achievement of a 71% objective response rate in a difficult to treat patient population continues to strengthen the evidence of our novel Versamune® platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer resulting in strong synergy with Bintrafusp alfa and NHS-IL12, thus leading to effective tumor regression,” commented Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. “The initial data solidifies our belief that PDS0101’s published preclinical efficacy, when combined with these two immune-modulating agents, demonstrates the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV-associated cancers who have limited treatment options.”

There are more than 630,000 cases of HPV-associated malignancies including cervical, oropharyngeal and anal cancer worldwide annually. HPV 16 is responsible for most of these cases. About 15-20% of HPV-associated malignancies respond to PD-(L)1 inhibitors. However, for the overwhelming majority of patients who progress on these immunotherapies there is no effective standard of care therapy.

The abstract is now available online on the ASCO conference website: https://am.asco.org/.

Abstract Number: 2501
Abstract Title: Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.

Presenting Author: Julius Strauss, MD, National Cancer Institute
Session: Developmental Therapeutics—Immunotherapy
Date: June 7, 2021
Time: 3:00 PM-6:00 PM EDT

Dr. Julius Strauss, Staff Clinician, LTIB, is serving as the Principal Investigator of this phase 2 clinical trial in advanced HPV-associated cancers. For patients interested in enrolling in this clinical study, please call NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email [email protected], and/or visit the website: https://trials.cancer.gov.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products may overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple investigational therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: [email protected]

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: [email protected]

*Updated data and results to be presented in June at the ASCO meeting
1C.S. Rumfield et al., J. Journal for ImmunoTherapy of Cancer 2020;8:e000612. doi:10.1136/jitc-2020-000612)
2S. Gandhapudi et al, J. Immunology, 2019 (202), 1215

The Technological Invasion in Cannabis Cultivation


image credit: Oregon Dept. of Agr. (Flikr)


Robotics and AI Are Being Tapped by Cannabis Growers

 

Increasing market demand and challenges in farming cannabis crops have prompted farms to seek technological upgrades to improve cultivation. Introducing robotics and artificial intelligence (AI) in Cannabis cultivation is having a massive impact on its production processes.

Related to cultivation, the use of tech has improved output and quality in a number of ways. Firstly, the crops are healthier. It has also made planting, monitoring, and harvesting more efficient. Companies are also integrating high tech into other stages of the production processes, from seed to delivery and right through to methods of consumption.

 

Why AI is a Game-Changer

Despite the upfront costs, high-tech saves growers money and increases output. With more states legalizing the use of cannabis, farmers benefit from a consistent product and improved yield. According to the Grand View Research Report, the “growing legalization and the adoption of marijuana for the treatment of chronic diseases are the key factors driving the growth of the market”. Dependability is critical for growers. Farmers are reinvesting profits to introduce technology that will improve the production process and resultant crops in order to satisfy market demand.

One advantage of the technological invasion of cannabis farming is it provides solutions to the planting environment issues. One solution is well-monitored indoor farming; this avoids many of the challenges of outdoor farming. From environmental challenges to the risk of cross-pollination, choosing indoor farming controls many key factors in producing cannabis.

Getting the THC concentration, temperature, and other figures right are key parts of farming cannabis in a monitored, legal setting. While indoor farming addresses these issues, it is expensive to maintain. With artificial intelligence, the management system is simpler and less expensive using automated systems and monitoring. It also can also aid the detection of pests and other threats.

The stakes are high for growers. The current global market for cannabis is $20.5 billion. Grand View Research has predicted that the global market for cannabis will be worth $73.6 Billion by 2027. With healthier, more consistent crops produced in larger quantities, some of this demand can be met without equal land expansion.

 

Cannabis Companies Benefitting from AI

High tech has found its way into the marijuana industry from seed through distribution. Below are three interesting publicly traded companies and information on how they’re benefiting from technology.

Medicine Man Technologies, Inc., d/b/a Schwazze (OTCQX: SHWZ), is a growing vertically integrated cannabis company located in Colorado but planning to spread its wings into other states. They operate seed to sale with work ethics that integrates customer-centric thinking and data science to test, measure, and drive decisions and outcomes in every stage of the production chain. Their implementation of technology in improving their operations is driven by their belief in the full potential of cannabis.

Sugarmade, Inc. (OTCMKTS: SGMD) is a company that improves customer satisfaction by integrating technology in service delivery. The delivery of cannabis is made easier and faster for customers with their technological approaches. Sugarmade has a portfolio of brands, within the recreational cannabis industry and outside, these include SugarRush, Budcars, NUG Avenue, and CarryOutsupplies.com.

Stem Holdings, Inc., d/b/a Driven by Stem (OTCQX: STMH), is a farm-to-home cannabis company providing solutions through high-tech innovation. Their business model is customer-driven as they have their own AI-based app delivery businesses throughout California that are expanding into the mature Oregon market.

 

 

Take-Away

Corporate farming of any kind relies on high tech, and cannabis is having its own set of demands and challenges, whether it is indoor or outdoor. Cannabis companies are increasing their reliance on data science and high-tech solutions like artificial intelligence to survive and improve success. With automated processes and machine-controlled methods, cannabis production is keeping up with the exponential growth that is set to reach new heights.

 

Suggested Content:

Will Federal Law Regarding Cannabis be Changed?

Cannabis Customers Served by “Ice Cream Truck” Delivery Model



Schwazze CEO, Justin Dye, and CFO, Nancy Huber Roadshow Replay (Video)

Stem Holdings C-Suite Interview with Adam Berk

 

Source:

https://www.grandviewresearch.com/press-release/global-legal-marijuana-market

https://www.globenewswire.com/news-release/2021/02/18/2177949/0/en/The-Worldwide-Cannabis-Industry-is-Projected-to-Reach-90-4-Billion-by-2026.html.

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Esports Entertainment Group Inc. Reports Fiscal 2021 Third Quarter Financial Results

 


Esports Entertainment Group, Inc. Reports Fiscal 2021 Third Quarter Financial Results

 

  • Third quarter Revenues of $5.4 Million, up 129% from previous quarter
  • Driven by completion of Lucky Dino asset purchase on 1st March
  • Performance bolstered by launch of SportNation.com and Vie.bet on Maltese Gaming Authority license during the quarter
  • Investment continued in building out Technology team and platform development as well as to achieve scale in back-office functions
  • Cash Jumps $11.3Million in 3Q21, Ending the Quarter at $16.9 Million with No Debt

Newark, New Jersey–(Newsfile Corp. – May 17, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (the “Company” or “EEG”), a diversified operator of esports, igaming and traditional sports betting businesses with a global footprint, today announced financial results for its fiscal 2021 third quarter ended March 31, 2021.

Fiscal 2021 Third Quarter Financial Results Highlights

  • Net revenue for 3Q21 of $5.4 million, up $5.4 million on 3Q20, (and up 129% as compared with 2Q21 net revenue of $2.4 million)
  • Gross profit (Net revenue less Cost of revenue) for 3Q21 of $3.1 million, up $3.1 million on 3Q20, (and up 199% as compared with $1.0 million in 2Q21)
  • Gross margin as a percentage of net sales in 3Q21 was 57.0%, (compared to 43.5% in 2Q21)
  • Sales and Marketing expenses of $2.4 million in 3Q21, up from $0.1m in 3Q20 (and compared to $1.9 million in 2Q21)
  • General and administrative expenses of $6.3 million in 3Q21, up from $0.5m in 3Q20 (and compared to $4.9 million in 2Q21)
  • Operating loss of $5.6 million in 3Q21, up from a loss of $0.6m in 3Q20 (and improved by 3% from a loss of $5.8 million in 2Q21)
  • Net loss of $12.4 million or $0.73 per basic common share in 4Q21, up from a net loss of $6.3m in 3Q20 or $1.02 per basic common share (and compared to a net loss of $7.3 million or $0.57 per basic common share in 2Q21)
  • Adjusted EBITDA* of -$2.1 million in 3Q21, compared to adjusted EBITDA of -$0.5m in 3Q20, and 44% improved from -$3.8 million adjusted EBITDA in 2Q21
  • Capital expenditures for 3Q21 of $0.7 million, up from $0.0m million in 3Q20 (and compared to $0.4m in 2Q21), as investment in Platform development continues
  • Stockholders’ equity at the end of 3Q21 increased by $50.0 million or 438% to $61.4 million from $11.4 million at the end of Fiscal 2020.

Operational Highlights

  • Completed asset purchase of Online Casino Operator Lucky Dino
  • Completed acquisition of Esports Gaming League (EGL), a provider of live and online events and tournaments
  • Closed $30 million registered direct offering priced at $15 per share
  • Vie.bet and SportNation.com brands launched on Malta Gaming Authority license, enabling operations in 150 jurisdictions globally
  • Filed New Jersey Gaming License Application
  • Signed exclusive Esports Tournament Partnerships with several pro-Sports teams, including the Baltimore Ravens, New England Patriots and Denver Broncos

*Adjusted EBITDA is a non-GAAP financial measure. Reconciliation is provided in the tables of this press release.

Management’s Comments

Our first quarter results were mainly driven by our acquisition of Lucky Dino combined with organic growth coming from our existing brands of Sportnation , EGL and Vie.gg.

We continue to execute on our organic growth strategy as well as acquire additional strategic esports and igaming assets.

Our recently announced partnerships with blue-chip professional sports organizations, are strong endorsements of this strategy. The imminent close of the previously announced GG circuit/Helix acquisition, combined with the recently announced intention to acquire Holodeck Media, will enable us to exponentially expand our technology-driven esports wagering, tournament play and igaming focused entertainment company.

We remain committed to the previously communicated full year fiscal 2021 revenue guidance, of $18m, and the Fiscal 2022 revenue guidance of $70m.

Our future is bright and we are very excited to continue our rapid expansion and growth driven by our unique assets and market position.

Fiscal 2021 Third Quarter Financial Results

Net revenues were $5.4 million for the three months ended March 31, 2021, as compared to $0.0million for the three months ended March 31, 2020, and were up by 129% (+$3.0m) when compared net revenues of $2.4m during the three-month period ended December 31, 2020. 9 months year-to-date revenues through 31st March, 2021 were $8.0m.

The quarter-on-quarter increase is primarily driven by the completion of the Lucky Dino Gaming Limited asset purchase on 1st March 2021, aided by the launch of both SportNation.com and Vie.bet into new jurisdictions under its Malta Gaming Authority (MGA) license

With the acquisition of Lucky Dino Gaming, Unique Active Players (“UAPs”) in the month of March across iGaming brands, rose to above 40,000, with Average Revenue per Player surpassing $80.

Total operating expenses for the three months ended March 31, 2021 totaled $11.0 million, an increase from the $0.6 million recorded for the three months ended March 31, 2020, and up from $8.1 million in the three-month period ending December 31, 2020. The increase was primarily attributable to the increased payroll, stock compensation, marketing, legal and professional services fees related to increased business activity.

Total net loss for the three months ended March 31, 2021 was $12.4 million, up from a loss of $6.3m in the three-month period ended March 31, 2020. This was principally driven by increased Equity Based Compensation, Transaction related costs, Depreciation and Change in the Fair value of Warrant liabilities, totaling $7.4 million between them.

*Adjusted EBITDA for the three months ended March 31, 2021 was -$2.1 million, up from -$0.6m in the three-month period ended March 31, 2020, but improved on the -$3.8m adjusted EBITDA in the three-month period ended December 31, 2020.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with Generally Accepted Accounting Principles (GAAP), the Company uses adjusted EBITDA, a non-GAAP financial measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses this non-GAAP financial measure for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that it provides useful information about operating results, enhances the overall understanding of past financial performance and future prospects, and allows for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP financial measure used by the Company in this press release may be different from the methods used by other companies.

We define and calculate Adjusted EBITDA as net loss before the impact of interest income or expense, income tax expense or benefit, depreciation and amortization, and further adjusted for the following items: stock-based compensation, transaction-related costs, non-core litigation, settlement and related costs, remeasurement of warrant liabilities, and certain other non-recurring, non-cash or non-core items, as described in the reconciliation below.

Adjusted EBITDA excludes certain expenses that are required in accordance with U.S. GAAP because they are non-recurring items (for example, in the case of transaction-related costs), non-cash expenditures (for example, in the case of depreciation, amortization, and stock-based compensation), or are not related to our underlying business performance (for example, in the case of interest income and expense and litigation settlement and related costs).

Esports Entertainment Group, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

March 31, June 30,
2021 2020
ASSETS
Current assets
Cash $ 16,880,683 $ 12,353,307
Restricted cash 3,428,366
Accounts receivable, net 153,011
Receivables reserved for users 1,486,024
Loans receivable 2,000,000
Other receivables 920,115
Deposit on business acquisition 500,000
Prepaid expenses and other current assets 1,423,581 263,345
Total current assets 26,291,780 13,116,652
Equipment, net 80,904 8,041
Operating lease right-of-use asset 546,012
Intangible assets, net 27,810,029 2,000
Goodwill 16,992,199
Other non-current assets 1,290,353 6,833
TOTAL ASSETS $ 73,011,277 $ 13,133,526
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses $ 5,305,176 $ 811,549
Liabilities to customers 3,218,798
Deferred revenue 145,091
Liabilities to be settled in stock 927,855
Notes payable – current 158,141
Operating lease liability – current 240,725
Contingent consideration 300,000
Total current liabilities 9,367,931 1,739,404
Notes payable 186,898
Deferred income taxes 1,729,138
Operating lease liability 322,205
TOTAL LIABILITIES 11,606,172 1,739,404
Commitments and contingencies (Note 13)
Stockholders’ equity
Preferred stock $0.001 par value; 10,000,000 shares authorized, none issued and
outstanding
Common stock $0.001 par value; 500,000,000 shares authorized, 20,166,740 and
11,233,223 shares issued and outstanding as of March 31, 2021 and June 30, 2020,
respectively 20,167 11,233
Additional paid-in capital 104,417,852 31,918,491
Accumulated deficit (42,077,212 ) (20,535,602 )
Accumulated other comprehensive loss (955,702 )
Total stockholders’ equity 61,405,105 11,394,122
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 73,011,277 $ 13,133,526

 

Esports Entertainment Group, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended March 31, Nine Months Ended March 31,
2021 2020 2021 2020
Net revenue $ 5,398,708 $ $ 7,983,293 $
Operating costs and expenses:
Cost of revenue 2,321,620 4,249,889
Sales and marketing 2,399,200 84,249 4,891,688 184,175
General and administrative 6,291,388 466,809 14,082,111 1,728,695
Total operating expenses 11,012,208 551,058 23,223,688 1,912,870
Operating loss (5,613,500 ) (551,058 ) (15,240,395 ) (1,912,870 )
Other income (expense):
Interest expense (23,479 ) (2,285,792 )
Net amortization of debt discount and premium on convertible debt (674,946 ) (1,225,205 )
Change in fair value of derivative liabilities (6,952,798 ) (5,865,451 )
Change in fair value of warrant liability (5,358,313 ) (4,729,924 )
Change in fair value of contingent consideration (1,305,804 ) (1,305,804 )
Loss on extinguishment of debt (2,795,582 )
Gain on warrant exchange 1,894,418 1,894,418
Other non-operating income (loss) (165,464 ) 32 (265,486 ) (25,779 )
Loss before income taxes (12,443,080 ) (6,307,831 ) (21,541,610 ) (12,216,261 )
Income tax
Net loss $ (12,443,080 ) $ (6,307,831 ) $ (21,541,610 ) $ (12,216,261 )
Basic and diluted loss per common share $ (0.73 ) $ (1.02 ) $ (1.54 ) $ (2.04 )
Weighted average number of common shares outstanding, basic and diluted 16,950,275 6,183,944 13,974,197 5,989,619

 

Adjusted EBITDA

The table below presents our Adjusted EBITDA reconciled to our net loss, the closest U.S. GAAP measure, for the periods indicated:

Esports Entertainment Group, Inc.

Adjusted EBITDA

Reconciliation to GAAP Results

Three months ended March 31, Nine months ended March 31,
2021 2020 2021 2020
Net loss $ (12,443,080 ) $ (6,307,830 ) $ (21,541,610 ) $ (12,216,261 )
Adjusted for:
Depreciation and amortization 882,951 2,486 1,687,161 18,013
Interest (income) expense, net 23,479 2,285,792
Stock-based compensation (1) 743,527 3,055,118 448,434
Transaction-related costs (2) 1,340,245 1,435,788
Litigation, settlement, and related costs (3) 508,689 508,689
Change in fair value of warrant liability 5,358,313 4,729,924
Change in fair value of contingent consideration 1,305,804 1,305,804
Loss on extinguishment of debt 2,795,582
Gain on warrant exchange (1,894,418 ) (1,894,418 )
Net amortization of debt discount and premium on convertible debt 674,946 1,225,205
Change in fair value of derivative liabilities 6,952,798 5,865,451
Other non-operating costs 165,464 33 265,486 25,779
Adjusted EBITDA $ (2,138,087 ) $ (548,506 ) $ (8,553,640 ) $ (1,446,423 )

 

(1) The amounts for the three months ended March 31, 2021 includes stock-based compensation expenses resulting from the issuance of equity awards to employees, non-employee directors and non-employee consultants for services.

(2) Includes transaction advisory, consulting, accounting and legal expenses for acquisition related activities

(3) Includes primarily external legal costs related to litigation and litigation settlement costs deemed unrelated to our core business operations.

Release – Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares


Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares

 

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021. Beginning at the open of trading on May 21, 2021, Onconova’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis.

At Onconova’s 2021 reconvened annual meeting of stockholders on April 30, 2021, Onconova stockholders authorized the Company’s Board of Directors to amend the Tenth Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split at a ratio in the range of one-for-five to one-for-fifteen. Onconova’s Board of Directors subsequently approved a reverse stock split ratio of one-for-fifteen, and the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation to effect the reverse stock split, which became effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware on May 20, 2021.

  • Upon effectiveness of the reverse stock split, each fifteen shares of Onconova’s common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share.
  • In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, warrants, and convertible preferred stock entitling the holders to purchase shares of our common stock. In particular, at the effective time of the reverse stock split, the Company adjusted its outstanding tradable warrants currently trading on the Nasdaq Capital Market under the symbol “ONTXW” in accordance with the terms of such tradable warrants to reflect the reverse stock split. As a result of these adjustments (and the adjustments effected on September 25, 2018 for a prior one-for-fifteen reverse stock split of the Company’s Common Stock), each tradable warrant now entitles its holder to purchase one- two hundred and twenty-fifth (1/225) of a share of Onconova’s common stock at an exercise price of $1,107.00 per share of common stock.
  • No fractional shares will be issued as a result of the reverse stock split. Instead, Onconova’s stockholders who otherwise would have been entitled to a fraction of a share, will receive a full share of common stock. If a holder of the tradable warrant would be entitled to receive a fraction of a share upon the exercise of the warrant, such fractional share will be rounded down to the nearest whole share. Fractional shares resulting from exercise of other common stock warrants and conversion of outstanding convertible preferred stock (if any) will be rounded in accordance with the terms of such securities.
  • The reverse stock split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares.

Onconova’s transfer agent, EQ Shareowner Services, will provide instructions to stockholders of record regarding the process for exchanging share certificates and all book-entry or other electronic positions representing issued and outstanding shares of Onconova common stock will be automatically adjusted.

Onconova’s common stock will continue to trade on the Nasdaq Capital Market under the trading symbol “ONTX.” The new CUSIP number for the common stock following the reverse stock split is 68232V 801.

In addition, at the Company’s reconvened 2021 Special Meeting of Stockholders on April 30, 2021, the Company’s stockholders also approved a proposal to amend the Certificate of Incorporation to decrease, upon the effectiveness of the Reverse Stock Split, the number of authorized shares of capital stock of the Company from 255,000,000 to 130,000,000 shares in order to decrease the number of authorized shares of common stock from 250,000,000 to 125,000,000 shares (the “Authorized Shares Decrease”). On May 20, 2021, the Company filed the Certificate of Amendment for Authorized Shares Decrease (the “Authorized Shares Decrease Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Authorized Shares Decrease Certificate of Amendment became effective on May 20, 2021 upon the effectiveness of the Reverse Stock Split.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

Release – Orion Group Holdings Inc. Announces Contract Awards of Approximately $17 Million

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $17 Million

 

HOUSTON–(BUSINESS WIRE)–May 20, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced three contract awards for its Concrete segment in each of its key markets, totaling approximately 
$17 million.

The Company was awarded a contract from  Hensel Phelps to provide concrete services for the new 
Royal Caribbean Cruise Terminal in the 
Port of Galveston, Texas. The 
$5.5 million project calls for paving and tilt-wall construction for the facility with work expected to start during the second quarter with completion expected later this year.

The Company was also awarded a 
$6.5 million project in 
San Antonio, Texas, that requires the construction of four tilt-wall buildings and associated paving. This work will begin in the third quarter and be completed by the fourth quarter of this year.

In addition, the Company was awarded a 
$5.1 million contract to construct multiple tilt-wall buildings and perform site paving for a new business park northwest of the 
Dallas-Fort Worth area. The work under this contract will begin in the third quarter and be completed by the second quarter of 2022.

“These project awards are a direct result of the quality and professionalism our team provides our customers,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “We are also extremely excited for  Hensel Phelps providing our team the opportunity to be involved in the new 
Royal Caribbean Cruise Terminal, as this work represents a great example of cross-selling opportunities between segments for our services.”

About Orion Group Holdings 

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States
Alaska
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
[email protected]
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Release – Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights


Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights

 

– Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Company’s employees –

– Increased R&D investments for the development of innovative delivery systems and for accelerating recruitment of patients in a clinical trial for oat beta glucan as a cholesterol reducer –

 First quarter 2021 sales increased 10% vs. first quarter 2020 –

EDMONTON, Alberta, May 20, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2021.

“While ensuring safety of our employees remained a top priority, we obtained solid results once again during the first quarter of this year and were successful at both growing our base business and also advancing some key research and development projects despite mandated stay-at-home orders in some Canadian provinces due to the ongoing COVID-19 pandemic. These results are a clear testament to the dedication and hard work of each of our employees during these challenging times and we are very proud of their commitment to support our customers heightened demand by delivering high quality products,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

  • Deployed additional efforts and resources in accelerating enrollment and randomization of patients for the clinical trial with beta glucan as a cholesterol reducer. To date, with outreach initiatives put in place by the team at the Montreal Heart Institute, more than 200 patients are part of the study. A total of 264 randomized patients are required for statistical significance.
  • Continued to monitor stability studies for liquid beta glucan and avenanthramides produced at Ceapro’s new manufacturing site as well as for the pharmaceutical-grade dry powder formulation of avenanthramides to be used in a human Phase 1 bioavailability and safety study.
  • Initiated the design of a protocol for a Phase 1 clinical trial with pharmaceutical grade avenanthramides. Subsequent to quarter end, signed a service agreement for the development and manufacturing of an oral solid dosage formulation of avenanthramide to be administrated during the Phase 1 study.
  • Conducted additional in vitro dose response study with PGX processed yeast beta glucan to correlate with upcoming McMaster animal study results. Animal studies should resume at the beginning of June 2021 upon lifting of stay-at-home orders in Ontario.
  • Developed and fine-tuned new PGX-dried chemical complexes mostly using sodium alginate as a carrier. Subsequent to quarter end, the Company announced the successful completion of its long-term research collaboration with University of Alberta. This project allowed for the expansion of a PGX pipeline which now includes proteins/enzymes in addition to polysaccharides like beta glucan. One of these enzymes, lysozyme was presented at the European Meeting on Supercritical Fluids by Dr. Ricardo Couto, a member of Ceapro’s PGX team who demonstrated that enzymatic activity is preserved following PGX processing. Lysozyme might have several applications since it is recognized as a remarkable natural antimicrobial and antiviral enzyme that boosts the immune defense while increasing shelf life in foods, cosmetics and pharmaceuticals. Lysozyme can also be integrated in skin care products to treat acne or promote wound repair.

Technology:

  • Upgraded and commissioned PGX pilot scale processing unit in Edmonton. This will allow the generation of larger and more consistent batches of PGX polymer carriers for impregnation scale-up.

  • Advanced the installation and further scaled up the PGX impregnation unit in Edmonton. Many trials were successfully conducted with the new impregnation vessel system mostly using sodium alginate.

  • Retained and conducted several virtual meetings with a seasoned high-pressure engineering and manufacturing company capable to design and build a new PGX industrial plant with equipment recently purchased in Germany. Timelines and cost estimates are being assessed.

Financial Highlights for the First Quarter Ended March 31, 2021

  • Total sales of $4,702,000 for the first quarter of 2021 compared to $4,273,000 for the comparative period in 2020; an increase of 10% over last year. Beta glucan sales volumes increased by 318% for Q1 2021 vs Q1 2020. With sales being made in US dollars, the decreased exchange rate $US/CDN as compared to the prior period negatively impacted 2021 sales by approximately $364,000.

  • Net profit of $515,000 for the first quarter of 2021 compared to a net profit of 1,126,000 for the comparative period in 2020.

  • Research and Development of $817,000 in Q1 2021 vs. $502,000 in 2020. This increased investment was partly due to an accelerated pace for the recruitment of patients for the beta glucan trial as a cholesterol reducer.

  • Cash generated from operations of $305,000 in Q1 2021 vs. $531,000 in Q1 2020.

  • Positive working capital balance of $8,246,972 as of March 31, 2021.

“As we respond to the potential impacts and uncertainties of COVID-19 by taking the necessary steps to preserve our financial position, we continue to execute on our expansion to a new business model from a contract manufacturer/commodity company to a high-value life science/biopharmaceutical company. We remain dedicated to executing on our milestones ahead and should the Company be able to service its customers without disruption, we strongly believe the prospects for the Company remain very strong for the upcoming year,” concluded Mr. Gagnon.

CEAPRO INC.    
Consolidated Balance Sheets    
Unaudited    
     
  March 31, December 31,
  2021 2020
  $ $
     
ASSETS    
Current Assets    
Cash and cash equivalents 5,239,071 5,369,029
Trade receivables 2,907,013 2,019,723
Other receivables 29,576 102,224
Inventories (note 3) 998,911 1,210,079
Prepaid expenses and deposits 198,804 348,845
     
  9,373,375 9,049,900
Non-Current Assets    
  Investment tax credits receivable 607,700 607,700
Deposits 82,124 82,124
Licences (note 4) 17,773 18,514
Property and equipment (note 5) 18,473,734 18,591,189
Deferred tax assets 874,304 874,304
     
  20,055,635 20,173,831
     
TOTAL ASSETS 29,429,010 29,223,731
     
LIABILITIES AND EQUITY    
Current Liabilities    
Accounts payable and accrued liabilities 791,089 1,067,622
Current portion of lease liabilities (note 6) 260,307 250,658
Current portion of CAAP loan (note 8) 75,007 72,263
     
  1,126,403 1,390,543
Non-Current Liabilities    
Long-term lease liabilities (note 6) 2,577,698 2,648,917
Deferred tax liabilities 874,304 874,304
     
  3,452,002 3,523,221
     
TOTAL LIABILITIES 4,578,405 4,913,764
     
Equity    
Share capital (note 7 (b)) 16,549,875 16,511,067
Contributed surplus (note 7 (e)) 4,669,347 4,682,393
Retained earnings 3,631,383 3,116,507
     
  24,850,605 24,309,967
     
TOTAL LIABILITIES AND EQUITY 29,429,010 29,223,731


CEAPRO INC.      
Consolidated Statements of Net Income and Comprehensive Income  
Unaudited      
     
     
  2021   2020  
Three Months Ended March 31, $   $  
       
Revenue (note 14) 4,701,743   4,273,374  
Cost of goods sold 2,443,800   1,901,223  
       
Gross margin 2,257,943   2,372,151  
       
Research and product development 816,847   502,542  
General and administration 712,207   865,034  
Sales and marketing 13,238   48,228  
Finance costs (note 11) 93,910   101,609  
       
Income from operations 621,741   854,738  
       
Other (expenses) income (note 10) (106,865 ) 271,317  
       
Income before tax 514,876   1,126,055  
       
Income taxes    
       
Total comprehensive income for the period 514,876   1,126,055  
       
Net income per common share (note 17):      
Basic 0.01   0.01  
Diluted 0.01   0.01  
       
Weighted average number of common shares outstanding (note 17):      
Basic 77,651,031   77,538,314  
Diluted 78,709,975   77,880,861  
       


CEAPRO INC.    
Consolidated Statements of Cash Flows    
Unaudited    
     
     
  2021   2020  
Three Months Ended March 31, $   $  
OPERATING ACTIVITIES    
Net income for the period 514,876   1,126,055  
Adjustments for items not involving cash    
Finance costs 36,166   40,947  
Transaction costs   554  
Depreciation and amortization 468,153   460,088  
Accretion 2,744   5,108  
Share-based payments 3,742   93,548  
Net income for the period adjusted for non-cash items 1,025,681   1,726,300  
CHANGES IN NON-CASH WORKING CAPITAL ITEMS    
Trade receivables (887,290 ) (264,398 )
Other receivables 72,648   (24,076 )
Inventories 211,168   (347,853 )
Prepaid expenses and deposits 72,574   (54,186 )
Accounts payable and accrued liabilities relating to operating activities (153,619 ) (463,443 )
Total changes in non-cash working capital items (684,519 ) (1,153,956 )
Net income for the period adjusted for non-cash and working capital items 341,162   572,344  
Interest paid (36,166 ) (40,947 )
CASH GENERATED FROM OPERATIONS 304,996   531,397  
INVESTING ACTIVITIES    
Purchase of property and equipment (253,018 ) (20,099 )
Purchase of leasehold improvements (19,472 )  
Accounts payable and accrued liabilities relating to investing activities (122,914 )  
CASH USED IN INVESTING ACTIVITIES (395,404 ) (20,099 )
FINANCING ACTIVITIES    
Stock options exercised 22,020    
Repayment of long-term debt   (48,520 )
Repayment of lease liabilities (61,570 ) (64,987 )
CASH USED IN FINANCING ACTIVITIES (39,550 ) (113,507 )
(Decrease) increase in cash and cash equivalents (129,958 ) 397,791  
     
Cash and cash equivalents at beginning of the period 5,369,029   1,857,195  
     
Cash and cash equivalents at end of the period 5,239,071   2,254,986  

The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Source: Ceapro Inc.

Release – Genprex Announces Participation in Noble Capital Markets Virtual Roadshow Series


Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

 

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

AUSTIN, Texas — (May 19, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will participate in Noble Capital Markets’ Virtual Roadshow Series, presented by Channelchek on May 20, 2021.

The virtual roadshow will feature a corporate presentation from Genprex’s President and Chief Executive Officer, Rodney Varner, followed by a Q & A session proctored by Noble Senior Research Analyst, Robert LeBoyer. Registration is free and open to all investors, at any level.

Noble Capital Markets’ Virtual Roadshow Series

Presentation Date: May 20, 2021

Presentation Time: 1-2 p.m. EDT

Registration Link: https://bit.ly/3hyiXcs

Noble’s research, as well as news and advanced market data on Genprex is available on Channelchek.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso alone

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
[email protected]

 

Release – Great Bear Provides First Detailed High-Grade Long Section


Great Bear Provides First Detailed High-Grade Long Section, Drills 22.79 g/t Gold Over 4.80 metres from Bedrock Surface, and Reaches 300 Reported LP Fault Drill Holes

 

May 19, 2021 – Vancouver, British Columbia, Canada – Great Bear Resources Ltd. (the “Company” or “Great Bear”, TSX-V: GBR; OTCQX: GTBAF) today reported results from its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario.

Chris Taylor, President and CEO of Great Bear said, “We are now entering the final months of near-surface maiden mineral resource estimation drilling of the central LP Fault zone, and are modeling 17 distinct high-grade gold domains within the broader LP Fault gold mineralized system. For the first time, we provide a detailed long section of the upper portion of one of these high-grade domains, a summary of all drill results within that long section, and detailed maps of the high-grade domains within the broader LP Fault gold system.”

Great Bear plans to release detailed high-grade and bulk tonnage domain information over the coming months. This news release includes the first of this information.

Figure 1: Upper 500 m x 250 m area of high-grade domain BR7, showing all results to date. New results are highlighted in orange.

Table 1: All 28 drill holes that intersect the near-surface portion of high-grade domain BR7, along 500 metres of strike length. New results in italics (holes BR-296-299). Note that assay intervals from previously reported drill holes have been clipped to domain BR7.

Drill Hole

From (m)

To (m)

Width* (m)

Gold (g/t)

BR-037

135.30

150.70

15.35

2.23

BR-038

81.20

87.80

6.60

2.96

BR-118

156.00

169.00

13.00

18.57

BR-119

46.60

57.00

10.40

1.45

BR-140

247.00

257.70

10.70

4.12

BR-142

231.00

239.30

8.25

2.53

BR-143

182.00

193.50

11.50

5.26

BR-144

130.00

144.30

14.25

15.31

BR-145

95.60

106.90

11.30

11.47

BR-146

35.75

45.55

9.80

86.97

BR-147

48.00

55.90

7.90

3.79

BR-172

84.00

91.50

7.50

1.12

BR-173

210.00

214.30

4.30

4.12

BR-174

207.00

216.00

9.00

13.82

BR-175

256.00

264.70

8.70

3.84

BR-211

99.80

105.60

5.80

7.80

BR-212

157.00

174.50

17.50

6.62

BR-213

240.30

245.00

4.70

3.66

BR-224

311.50

328.40

16.90

1.16

BR-225

231.75

243.20

11.45

1.50

BR-231

151.00

157.00

6.00

3.43

BR-232

106.20

111.00

4.80

53.72

BR-233

78.30

84.85

6.55

3.63

BR-281

170.25

174.00

3.75

1.04

BR-296

27.30

32.80

5.50

3.52

BR-297

31.00

32.60

1.60

3.98

BR-298

55.25

63.10

7.85

14.72

BR-299

53.90

64.25

10.35

4.12

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time. Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts. Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade.

Figures 1, 2, 3, 4 and 5 respectively show: 1) A detailed long section of high-grade domain “BR7”, which is one of 17 high-grade domains currently being drilled, 2) a map of all high-grade domains within the LP Fault, 3) A more detailed map of the high-grade domains in the central LP Fault zone, including surrounding bulk tonnage style mineralization, and 4) two cross sections through high-grade domain BR7. Table 1 provides all gold intercepts from BR7 shown in Figure 1. Table 2 provides all new gold assay results from the most recent LP Fault drilling.

With the 17 drill holes included in this release, Great Bear has released 300 LP Fault drill holes to date.

Highlights of Current Results

  • New drill holes reported in this release intersected the LP Fault zone from approximately 20 to 500 metres vertical depth along 2.2 kilometres of strike length.
  • Drill holes were located a) above previous drilling, in order to extend gold mineralization towards surface, and b) within 75 to 100 metre previously undrilled gaps in the zone.
  • Two drill holes are step-ups that extend gold mineralization by more than 75 metres above previous drilling to the near-surface:
    • BR-298 assayed 22.79 g/t gold over 4.80 metres from 58.30 to 63.10 metres downhole, within a broader mineralized interval assaying 3.32 g/t gold over 43.80 metres from 29.70 to 73.50 metres downhole.
    • BR-299 assayed 13.27 g/t gold over 2.35 metres from 34.90 to 37.25 metres downhole, and 4.12 g/t gold over 10.35 metres from 53.90 to 64.25 metres downhole. The total mineralized interval was 2.30 g/t gold over 39.30 metres from 32.20 metres to 71.50 metres downhole.
  • New bulk-tonnage type intercepts include:
    • 3.07 g/t gold over 35.60 metres from 117.00 to 152.60 metres downhole in drill hole BR-320.
    • 1.11 g/t gold over 91.60 metres from 349.50 to 441.10 metres downhole in drill hole BR-285.
    • 1.00 g/t gold over 91.40 metres from 473.60 to 565.00 metres downhole in drill hole BR-286.
  • Drill holes with multiple intervals of gold mineralization including both high-grade and bulk tonnage type results include:
    • BR-276 which assayed 25.57 g/t gold over 2.50 metres from 233.50 to 236.00 metres downhole, and 4.10 g/t gold over 23.85 metres from 462.25 to 486.10 metres downhole, including a high-grade core of 68.40 g/t gold over 0.95 metres from 485.15 to 486.10 metres downhole.

Results continue to demonstrate excellent continuity of high-grade and bulk-tonnage gold mineralization. The LP Fault zone remains open to extension in all directions.

Figure 2: Map of the 17 high-grade domains currently being drilled and modeled along the LP Fault. BR7 is left of centre.

Figure 3: Plan map of the various high-grade gold domains currently being drilled along the central LP Fault. Bulk tonnage style gold mineralization is also shown. The locations of drill holes reported in this release are shown.

Table 2: Current drill results from the LP Fault. Results are arranged by drill section from southeast (top) to northwest (bottom).

Drill Hole

 

From (m)

To (m)

Width* (m)

Gold (g/t)

Section

BR-287

 

375.00

388.25

13.25

1.21

19825

BR-320

 

47.00

48.00

1.00

8.59

20000

 

and

93.20

108.00

14.80

1.66

 

 

including

96.35

97.50

1.15

15.50

 

 

and

117.00

152.60

35.60

3.07

 

 

including

118.00

120.70

2.70

6.64

 

 

and including

130.50

133.00

2.50

4.77

 

 

and including

138.90

152.60

13.70

5.18

 

 

and including

138.90

139.50

0.60

24.40

 

 

and including

150.45

150.95

0.50

53.50

 

BR-299

 

32.20

71.50

39.30

2.30

20600

 

including

34.90

37.25

2.35

13.27

 

 

and including

34.90

35.90

1.00

23.40

 

 

and including

53.90

64.25

10.35

4.12

 

BR-298

 

29.70

73.50

43.80

3.32

20625

 

including

55.25

63.10

7.85

14.72

 

 

and including

58.30

63.10

4.80

22.79

 

 

and including

60.80

61.30

0.50

161.00

 

BR-297

 

31.00

50.10

19.10

0.99

20675

 

including

31.00

32.60

1.60

3.98

 

BR-296

 

27.30

51.50

24.20

1.39

20750

 

including

27.30

32.80

5.50

3.52

 

BR-286

 

473.60

565.00

91.40

1.00

21125

 

including

473.60

482.00

8.40

3.27

 

 

and including

481.20

482.00

0.80

18.40

 

 

and including

502.20

502.80

0.60

52.30

 

BR-285

 

349.50

441.10

91.60

1.11

21150

 

including

354.00

362.55

8.55

8.26

 

 

and including

356.50

358.50

2.00

31.20

 

BR-277

 

517.25

521.00

3.75

0.82

21750

 

including

517.25

518.35

1.10

1.52

 

BR-263

 

585.50

591.50

6.00

1.06

21850

 

including

589.65

590.20

0.55

3.81

 

BR-264

 

548.50

580.20

31.70

1.48

21850

 

including

552.75

558.00

5.25

5.15

 

 

and including

552.75

554.30

1.55

12.01

 

 

and including

557.05

558.00

0.95

6.42

 

BR-265

 

420.85

421.40

0.55

5.64

21900

 

and

503.20

504.30

1.10

6.05

 
 

BR-302

 

356.00

368.50

12.50

2.47

21975

 

including

359.25

359.75

0.50

57.00

 

 

and

421.20

430.00

8.80

1.13

 

Table 2 continued

Drill Hole

 

From (m)

To (m)

Width* (m)

Gold (g/t)

Section

BR-276

 

225.60

236.00

10.40

6.63

22000

 

including

233.50

236.00

2.50

25.57

 

 

and

258.45

258.95

0.50

19.50

 

 

and

311.85

316.00

4.15

2.19

 

 

including

314.05

314.65

0.60

10.50

 

 

and

389.60

396.75

7.15

5.85

 

 

including

392.25

395.25

3.00

12.70

 

 

and

462.25

486.10

23.85

4.10

 

 

including

483.45

486.10

2.65

28.01

 

 

and including

485.15

486.10

0.95

68.40

 

BR-278

 

212.00

213.00

1.00

5.84

22000

 

and

226.50

237.00

10.50

2.13

 

 

including

232.80

233.30

0.50

41.80

 

BR-301

 

353.00

354.50

1.50

2.93

22000

 

and

560.55

561.10

0.55

3.49

 

BR-300

 

319.20

322.75

3.55

1.06

22025

 

and

468.30

471.30

3.00

1.03

 

* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time. Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts. Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade

About High-Grade Gold Domains and BR7

The 17 high-grade domains are structurally and geologically distinctive from the surrounding lower grade, bulk tonnage style gold mineralization. Together, they span a strike length of 4.2 kilometres and occur within eight larger stratigraphically controlled lower grade domains. They are characterized by high degrees of strain and/or transposed quartz vein zones following two distinct structural fabrics and transition from upper greenschist to lower amphibolite facies metamorphism. Gold in the high-grade domains is generally observed as free gold, is often transposed into, and overgrows the dominant structural fabrics, and is higher-grade on average than the surrounding bulk tonnage gold zones.

Domain BR7, presented in this news release, has a surface strike length of 620 metres and has been drilled to a depth of 500 metres (where it remains open to extension).  BR7 is a high strain zone hosted within strongly altered (albite, biotite, +/- quartz veined) felsic volcanic rocks and occurs oblique to the dominant geological contacts. It has an average strike orientation of 270 degrees and dips 74 degrees to the north.

Drilling is planned to intersect the various high-grade domains at 40 – 50 metre spacing. Figure 1 demonstrates how drilling is nearing completion within the upper portions of domain “BR7”, with few drill holes now required to provide the desired drill density for upcoming maiden resource estimation. Drilling is also nearing completion in the near-surface portions of all 17 high-grade domains along more than 4 kilometres of strike length of the central LP Fault. This drilling is expected to be completed from surface to an average of approximately 400 metres depth by year end.

Figure 4: Cross section 20675 showing the location of high-grade domain BR7 relative to the adjacent high-grade domains, within the broader LP Fault gold system. New results in yellow including an inset of gold mineralization from BR-298. Image is of a selected interval and does not represent all gold mineralization on the property.

Figure 5: Cross section 20625 showing the location of high-grade domain BR7 relative to the adjacent high-grade domains, within the broader LP Fault gold system. New results in yellow.

Great Bear’s progress can be followed using the Company’s plan maps, long sections and cross sections, and through the VRIFY model posted at the Company’s web site at www.greatbearresources.ca. All LP Fault drill hole highlighted assays, plus drill collar locations and orientations can also be downloaded at the Company’s web site.

Drill collar location, azimuth and dip for drill holes included in this release are provided in the table below (UTM zone 15N, NAD 83):

Hole ID

Easting

Northing

Elevation

Length

Dip

Azimuth

BR-263

456097

5635122

374

639

-56

222

BR-264

456097

5635122

374

642

-58

235

BR-265

455959

5635089

373

657

-68

222

BR-276

455897

5635136

374

570

-66

220

BR-277

456117

5635007

373

594

-61

220

BR-278

455899

5635139

374

540

-60

225

BR-285

456570

5634607

359

621

-62

220

BR-286

456643

5634693

361

624

-58

218

BR-287

457838

5634151

363

630

-54

208

BR-296

456767

5634155

357

204

-55

213

BR-297

456807

5634141

357

120

-56

210

BR-298

456854

5634122

357

117

-55

210

BR-299

456922

5634125

356

168

-56

210

BR-300

455929

5635241

375

666

-54

225

BR-301

455968

5635212

374

678

-61

226

BR-302

455968

5635212

374

628

-60

222

BR-320

457521

5633960

351

225

-46

222

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes. These mineralization styles are also typical of the significant mined deposits of the Red Lake district.
  • High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault). The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property. High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals. The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration. Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 330 km2 of highly prospective tenure across 5 projects: the flagship Dixie Project (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), the Sobel Property (earning a 100% interest), and the Red Lake North Property (earning a 100% interest) all of which are accessible year-round through existing roads.

QA/QC and Core Sampling Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario. Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods. Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab. Selected samples are also chosen for duplicate assay from the coarse reject of the original sample. Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay. Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC). No QAQC issues were noted with the results reported herein.

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD

“Chris Taylor”                                      

Chris Taylor, President and CEO

Investor Inquiries:
Mr. Knox Henderson
Tel: 604-646-8354
Direct: 604-551-2360
[email protected]
www.greatbearresources.ca

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Release – Boomer Holdings Announces 6 Month Transitional Period Results

 


Boomer Holdings Announces 6 Month Transitional Period Results

 

LAS VEGAS, May 18, 2021 /PRNewswire/ — Boomer Holdings, Inc. (“Boomer” or the “Company”) (OTCQB: BOMH), is an innovative Consumer Products Company specializing in a large variety of premium quality wellness and everyday use products under the Boomer Naturals brand name. Boomer reported results for its six -month transition period ended January 31, 2021.

On January 29, 2021 the Company changed its fiscal year-end from July 31st to January 31st. As required, on May 17, 2021, Boomer Holdings, Inc.  filed a transition report on Form 10-KT with the Securities and Exchange Commission covering the transition period from August 1, 2021 to January 31, 2021.

Financial highlights for Boomer Holding Corp’s six-month transition period ended January 31st are as follows:

  • 6-month revenue of $45.1 million, a gain of over $30 million over the prior 12-month period of $11.4 million (ended 7/31/20)
  • Net income for the 6-month period was $7.3 million, a gain of over $20 million over the $15.6 million dollar loss from the prior 12-month period
  • Gross margins of 64% during the past six-month period
  • Stockholder deficit at 1/31/21 was reduced to $(4.7) million from the 7/31/20 deficit of $(12) million

Significant growth was achieved during the six-month transition period, which led to overall earnings per share to move from $(0.12) to $0.05.

“We are pleased to report the progress made in the Form 10-KT to our shareholders,” said Mike Quaid, CEO of Boomer Holdings.

“We were able to enjoy continued success in the Personal Protective Equipment (PPE) category while using that success to prepare for the next phase of Boomer Holdings growth.” Said Daniel Capri, President and Chairman of the Board, “as the country turns the corner on the pandemic and PPE demand slows, we believe Boomer is positioning itself to replace and eventually exceed that demand through our many new and exciting lines of products.”

Operational achievements of note:

  • Boomer established a strong retail presence in over 8,000 CVS stores
  • Boomer has prepared and is readying its new product lines to roll out in the first and second quarters of 2022 featuring:
    • Vietnamese Coffee
    • Unique nutritional powder formulations
    • Silver infused clothing
    • Silver infused bedding

Stated Mike Quaid, “Building an efficient and stable manufacturing and distribution from Vietnam is a goal that has thwarted many companies that have tried. I am pleased to announce that Boomer has completed this task and will now focus on bringing these unique and in-demand products to the American market. We look forward to further announcements about Boomer products and distribution in the coming weeks.”

About Boomer Naturals
Boomer Naturals is a wholly-owned subsidiary of Boomer Holdings Inc., a publicly-traded company (OTCQB: BOMH). Boomer Naturals is a full-service wellness company that provides products and services that enhance your well-being and increase your quality of life. Boomer Naturals’ products are available online at Boomerstore.com, BoomerNaturals.com, BoomerNaturalsWholesale.com, CVS.com. Boomer Naturals’ products are also available at the Boomer Naturals retail store, CVS retail locations, and resorts and golf shops across the country. For more information, please visit www.boomernaturals.com.

Forward-Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, except as required by securities laws. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company’s control, risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19), and those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”). There may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.

CONTACT: Mike Quaid, [email protected]

SOURCE Boomer Naturals, Inc